Why the U.S. Needs a Unified Cannabis Regulation Framework
Cannabis laws in the U.S. are a tangled mess. Consumers are confused, businesses are scrambling, and policymakers can’t keep up. One state welcomes dispensaries, while its neighbor enforces strict bans—yet in that same restrictive state, you might find what looks like a legal weed cart selling intoxicating products on the street. And despite growing public acceptance, federal law still classifies cannabis alongside heroin.
The 2018 Farm Bill only added to the confusion. Intended to legalize hemp-derived products with less than 0.3% THC, it inadvertently created a loophole that flooded the market with intoxicating cannabinoids like Delta-8 and Delta-10 THC. The result? More regulatory uncertainty and inconsistent enforcement. Let’s explore why a cohesive federal framework is essential for resolving these issues and creating a fair and functional cannabis regulatory system.
Learn more about cannabinoids in the FREE Medical Cannabis Class.
The Confusing State of Cannabis Laws in the U.S.
Recreational Cannabis: Over 20 states have legalized cannabis for adult recreational use, each with unique rules on possession, sales, and cultivation. Take a look at the legal status of cannabis in your state here.
Medical Cannabis: Most states allow medical cannabis with a valid prescription or medical marijuana card. However, qualifying conditions, access to products, and regulations differ widely, making it challenging for patients to navigate.
FDA-Approved Cannabis-Based Drugs: A few FDA-approved drugs, such as Epidiolex, Marinol, Syndros, and Cesamet, are available by doctor prescription and are legal in all 50 states. These medications are primarily used to treat conditions like epilepsy, nausea, and appetite loss.
Prohibition States: Several states still prohibit cannabis entirely, leaving consumers and businesses to navigate conflicting laws.
Medical Cannabis: Most states allow medical cannabis with a valid prescription or medical marijuana card. However, qualifying conditions, access to products, and regulations differ widely, making it challenging for patients to navigate.
FDA-Approved Cannabis-Based Drugs: A few FDA-approved drugs, such as Epidiolex, Marinol, Syndros, and Cesamet, are available by doctor prescription and are legal in all 50 states. These medications are primarily used to treat conditions like epilepsy, nausea, and appetite loss.
Prohibition States: Several states still prohibit cannabis entirely, leaving consumers and businesses to navigate conflicting laws.
The 2018 Farm Bill and Its Impact on Cannabinoid Confusion
The 2018 Farm Bill federally legalized hemp products containing less than 0.3% delta-9 THC but inadvertently created loopholes:
- Loopholes for Intoxicating Cannabinoids: Delta-8 THC and Delta-10 THC remain federally legal, but many states have banned or restricted their sale.
- Consumer Confusion: These gray areas leave consumers unsure about what is allowed, especially when traveling between states.
- Unintentional Intoxication: With little regulation, consumers may unknowingly purchase products containing intoxicating cannabinoids, mistaking them for non-intoxicating alternatives like CBD.
- Product Variation in Strength and Quality: The lack of oversight has led to wide variations in the strength, purity, and safety of cannabinoid products, increasing the risk of unintended effects and health concerns.
The Best Path Forward for Federal Cannabis Regulation
To simplify the cannabis regulatory landscape, cannabis should be removed from Schedule 1. The focus should be on federal action that empowers states to regulate cannabis independently while addressing consumer confusion around hemp-derived cannabinoids.
Why Rescheduling Cannabis Is Key
Rescheduling cannabis is a critical step toward addressing the social, economic, and scientific inequities caused by its classification as a Schedule I substance—a designation that inaccurately equates it with drugs like heroin and severely limits its potential benefits. Here’s why removing cannabis from Schedule I is essential:
1. Social Equity
The classification of cannabis as a Schedule I drug has disproportionately harmed marginalized communities, leading to significant racial disparities in arrests and convictions. Rescheduling cannabis would:
- Reduce these inequities by eliminating federal penalties for cannabis possession.
- Enable the expungement of non-violent cannabis-related convictions, giving individuals a fresh start.
- Open the cannabis industry to entrepreneurs from disadvantaged backgrounds by removing federal barriers to entry.
2. IRS Implications (Tax Code 280E)
3. Support for Medical and Scientific Research
Should the 2018 Farm Bill Be Revised?
From a practical standpoint, leaving the Farm Bill unchanged may be the best option for now. States can regulate cannabinoids like Delta-8 THC under their broader cannabis laws, while federal rescheduling reduces the need for federal oversight of hemp-derived products.
A Practical Solution for Cannabis Regulation in the U.S.
The current state-by-state cannabis patchwork is unsustainable. Rescheduling cannabis at the federal level and empowering states to regulate cannabis independently would provide clarity, improve safety, and unlock economic and scientific opportunities.
The 2018 Farm Bill may not require immediate revision, but its role in shaping the hemp industry underscores the need for thoughtful consideration. Whether it remains unchanged or is refined, the focus should be on addressing consumer confusion and supporting state-based regulation.
A unified framework doesn’t mean federal control—it means providing a solid foundation for states, businesses, and individuals to navigate the cannabis market confidently. By prioritizing rescheduling and respecting state sovereignty, the U.S. can lead the way in creating a thriving, consistent cannabis industry.
Created with
